BDB-001 + cyclophosphamide + glucocorticoids

This is a combination therapy consisting of **BDB-001** (a monoclonal antibody against complement protein C5a), **cyclophosphamide** (an alkylating chemotherapy and immunosuppressant), and **glucocorticoids** (corticosteroids, such as prednisone). BDB-001 is designed to block C5a-mediated inflammation and neutrophil activation by binding C5a, a key proinflammatory molecule in the complement cascade, thus reducing C5a-driven inflammatory damage[1][2]. Cyclophosphamide inhibits DNA replication and immune cell proliferation, commonly used to treat autoimmune diseases and malignancies. Glucocorticoids provide broad anti-inflammatory and immunosuppressive effects to control disease activity. In clinical studies for **ANCA-associated vasculitis (AAV)**, this combination—sometimes with reduced glucocorticoid doses—achieved disease remission and allowed reduction in steroid use, indicating potential for lowering glucocorticoid toxicity while maintaining disease control[2].